NCT01315795View on ClinicalTrials.gov

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Polycystic Liver Disease
Interventions
DRUG

Lanreotide Autogel 90 mg and 120 mg

administration of lanreotide sc every 4 weeks (28 days)

Trial Locations (1)

3000

UZ Leuven, Gasthuisberg, Leuven

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT01315795 - Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease | Biotech Hunter | Biotech Hunter